This Article Full Text Full Text (PDF) All Versions of this Article: 28/3/s25    most recent ATVBAHA.107.160481v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Patrono, C. Articles by Rocca, B. Search for Related Content PubMed PubMed Citation Articles by Patrono, C. Articles by Rocca, B.

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28:s25.)
© 2008 American Heart Association, Inc.

Translational Therapeutics at the Platelet Vascular Interface: A CME-Certified Activity

Aspirin: Promise and Resistance in the New Millennium

Carlo Patrono; Bianca Rocca

From the Department of Pharmacology, Catholic University School of Medicine, Rome, Italy.

Correspondence to Carlo Patrono, MD, Istituto di Farmacologia, Università Cattolica del Sacro Cuore, Largo F. Vito 1, 00168 Rome, Italy. E-mail carlo.patrono{at}rm.unicatt.it

Although conceived at the end of the 19th century, aspirin remains the gold standard of antiplatelet therapy. Approximately 100 randomized clinical trials have established its efficacy and safety in the prevention of myocardial infarction, ischemic stroke, and vascular death among high-risk patients treated for a few weeks, at one end of the spectrum, and in low-risk subjects treated up to 10 years at the other. Despite this wealth of data, several issues continue to be debated concerning the use of aspirin as an antiplatelet agent, and novel opportunities appear on the horizon for this 110-year-old drug. These issues include: (1) the optimal dose for cardiovascular prophylaxis; (2) the uncertain threshold of cardiovascular risk for its use in primary prevention; (3) the apparent gender-related difference in its cardioprotective effects; (4) the increasingly popular theme of aspirin "resistance"; (5) the opportunities of chemoprevention in colorectal cancer; and (6) the renewed interest in aspirin as an analgesic agent in osteoarthritic patients at high cardiovascular risk. The aim of this review is to address these issues by integrating our current understanding of the molecular mechanism of action of the drug with the results of clinical trials and epidemiological studies of aspirin as an antiplatelet drug.

Key Words: antiplatelet therapy • aspirin resistance • primary prevention • colorectal cancer • osteoarthritis

This article has been cited by other articles:

				L. A. Holowatz, J. D. Jennings, J. A. Lang, and W. L. Kenney Ketorolac alters blood flow during normothermia but not during hyperthermia in middle-aged human skin J Appl Physiol, October 1, 2009; 107(4): 1121 - 1127. [Abstract] [Full Text] [PDF]

				L. A. Holowatz and W. L. Kenney Reply to Mahe, Rousseau, Saumet, and Abraham J Appl Physiol, April 1, 2009; 106(4): 1472 - 1472. [Full Text] [PDF]

				L. A. Holowatz and W. L. Kenney Chronic low-dose aspirin therapy attenuates reflex cutaneous vasodilation in middle-aged humans J Appl Physiol, February 1, 2009; 106(2): 500 - 505. [Abstract] [Full Text] [PDF]